From Underperformance to Opportunity Biotechs Case for 2025
By Christopher Gannatti Key Takeaways Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking innovations like mRNA cancer vaccines and CRISPR-based therapies. Structural shifts, including …